Drug intelligence / Profile preview

BHVI-3

Development stage: Unknown
Lead developer: Brien Holden Vision Institute
Modality: Small Molecules
Administration: Ophthalmic

Overview

BHVI-3 is an investigative small molecule eye drop drug developed by Brien Holden Vision Institute for the treatment of myopia and other eye diseases. It is a combination of two small molecule compounds, BHVI-1 and BHVI-2, designed to slow or halt the progression of myopia in children. The developmental status is currently pending, with phase 1/2 clinical trials completed in children with myopia. The combination is administered topically as eye drops. Further mechanistic and molecular details have not been disclosed in the available public literature[6].

Other names: atropine + caffeine

Targets

CHRM3 (M3)ADORA2B (Adenosine A2B receptor)CHRM2 (M2)ADORA2A (Adenosine A₂A Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM5 (M5)ADORA1 (Adenosine receptor A1 subtype)CHRM4 (M4)

Beyond the preview

Go deeper on BHVI-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHVI-3.

Explore the full profile